
| Clot phase           | Parameter                                            | Measurement                                                           | TEG abbreviation                                                | ROTEM abbreviation                                                                                              | Enzymatic stage                                                                                   | Abnormalities                                                                                                           |
| -------------------- | ---------------------------------------------------- | --------------------------------------------------------------------- | --------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------- |
| **Clot initiation**  | Clotting time                                        | Time from start of sample to 2 mm clot amplitude                      | Reaction time (R)                                               | Clot time (CT)                                                                                                  | Early activation of clotting cascade resulting in initial thrombin burst                          | Prolonged by clotting factor deficiencies, anticoagulants, and hypofibrinogenemia. Shortened in hypercoagulable states. |
| **Clot kinetics**    | Clot formation time                                  | Time from 2 to 20 mm clot amplitude                                   | Clot formation time (K)                                         | Clot formation time (CFT)                                                                                       | Clot potentiation by activation of platelets and thrombin-mediated cleavage of soluble fibrinogen | Prolonged by clotting factor deficiencies, hypofibrinogenemia, thrombocytopenia, and platelet dysfunction.              |
| Angle                | Angle of tangent line from 2 to 20 mm clot formation | Alpha angle                                                           | Alpha angle                                                     | Abnormally low in clotting factor deficiencies, hypofibrinogenemia, thrombocytopenia, and platelet dysfunction. |                                                                                                   |                                                                                                                         |
| **Clot strength**    | Maximal clot strength                                | Amplitude measured at peak clot strength                              | Maximal amplitude (MA)                                          | Maximal clot firmness (MCF)                                                                                     | Maximal clot strength achieved via GP IIb/IIIa-mediated platelet-fibrin interactions              | Abnormally low in hypofibrinogenemia, thrombocytopenia, or platelet dysfunction.                                        |
| Clot viscoelasticity | Calculated from maximal amplitude                    | G                                                                     | Maximal clot elasticity (MCE)                                   | Abnormally high in platelet hypercoagulability.                                                                 |                                                                                                   |                                                                                                                         |
| **Clot lysis**       | Clot lysis                                           | Percentage of loss of amplitude at fixed time after maximal amplitude | Lysis at 30 minutes (LY30), estimated percentage of lysis (EPL) | Lysis index at 30 minutes (LI30), maximal lysis (ML)                                                            | Activation of fibrinolytic system                                                                 | Abnormally high in enzymatic or mechanical hyperfibrinolysis.                                                           |
![[Pasted image 20240323112027.png]]